CN110938077B - Method for synthesizing Avapritinib - Google Patents
Method for synthesizing Avapritinib Download PDFInfo
- Publication number
- CN110938077B CN110938077B CN201911359971.4A CN201911359971A CN110938077B CN 110938077 B CN110938077 B CN 110938077B CN 201911359971 A CN201911359971 A CN 201911359971A CN 110938077 B CN110938077 B CN 110938077B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- ethanol
- compound represented
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The invention relates to a method for synthesizing avapritinib. Compared with the existing synthetic route, the method has the advantages of multiple reaction steps, low yield and good experimental operability, and chiral compounds are resolved by using a chiral column.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a method for synthesizing Avapritinib.
Background
Avapritinib (BLU-285) is a small molecule kinase inhibitor and can effectively inhibit the activity of PDGFR alpha D842V mutant; and also as inhibitors of KIT mutations (KIT D816V). Avapritinib selectively and potently inhibits KIT and PDGFRA mutant kinases. Avapritinib has been shown to have broad inhibitory effects on gastrointestinal stromal tumor (GIST) associated KIT and PDGFRA mutations, including potent activity against activating loop mutations associated with resistance to currently approved therapies. Compared with approved multi-kinase inhibitors, avapritinib has significantly higher selectivity for KIT and PDGFRA than other kinases. Avapritinib has been FDA-granted a breakthrough medication eligibility to treat patients with PDGFR α D842V mutation, unresectable, or metastatic GIST. In addition, avapritinib has been granted 2 fast channel qualifications by the FDA: (1) treating GIST patients carrying a PDGFR α D842V mutation, regardless of the previously received therapy; (2) GIST patients who underwent disease progression after treatment with imatinib and a second tyrosine kinase inhibitor. Data published in the annual meeting of the American Society for Clinical Oncology (ASCO) in 2019 show that the overall remission rate of patients with rapritinib treated GIST carrying the PDGFR α D842V mutation is 86%; the total remission rate for treatment of the quadrifilar GIST patients was 22%, with a median duration of remission of 10.2 months.
The structural formula of Avapritinib is shown as formula I:
the current method for synthesizing Avapritinib remains to be improved.
Disclosure of Invention
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art. To this end, it is an object of the present invention to propose a method for synthesizing Avapritinib. The method does not need to use a chiral column to split chiral compounds, reduces the reaction steps, improves the total yield of the reaction, and effectively reduces the cost of final products.
In one aspect of the invention, the invention provides a process for preparing a compound of formula I, Avapritinib. According to an embodiment of the invention, the method comprises:
(1) contacting a compound represented by formula 1 with L-dibenzoyltartaric acid (L-DBTA) to obtain a compound represented by formula 2;
(2) contacting a compound represented by formula 2 with a compound represented by formula 3 to obtain a compound represented by formula 4;
(3) contacting a compound of formula 4 with said base to obtain a compound of formula I, Avapritinib,
the inventor finds that the compound shown in the formula I can be quickly and effectively prepared by adopting the intermediate compound 1 which is easily obtained at present as a starting material, carrying out chemical resolution on the intermediate compound 1 by using L-DBTA, carrying out halogenation reaction, and then removing the L-DBTA. Compared with the existing synthetic route, the synthetic method has the advantages of multiple reaction steps and low yield, and chiral compounds are resolved by using a chiral column, so that the synthetic method greatly reduces the reaction steps, improves the total yield of the reaction, effectively reduces the cost of final products, and has good experimental operability.
The term "contacting" as used herein is to be understood broadly and can be any means that enables a chemical reaction of at least two reactants, such as mixing the two reactants under appropriate conditions. The reactants to be contacted may be mixed with stirring as necessary, and thus, the type of stirring is not particularly limited, and may be, for example, mechanical stirring, that is, stirring under the action of a mechanical force.
Herein, a "compound of formula N" is also sometimes referred to herein as "compound N", where N is any integer from 1 to 4, e.g., "compound of formula 2" may also be referred to herein as "compound 2".
The terms "first", "second" and "first" are used herein for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present invention, "a plurality" means two or more unless specifically defined otherwise.
According to an embodiment of the present invention, the above method for preparing the compound represented by formula 2, the compound represented by formula 4, and the compound represented by formula I may further have at least one of the following additional technical features:
the chemical reactions described herein may be performed according to any method known in the art, according to embodiments of the present invention. The source of the raw materials for preparing the compound represented by formula 2, the compound represented by formula 4, and the compound represented by formula I is not particularly limited, and it may be prepared by any known method or may be commercially available.
According to an embodiment of the present invention, the contacting manner of the compound represented by formula 1 with L-DBTA in step (1) is not particularly limited. Therefore, the contact efficiency of the compound shown in the formula 1 and L-DBTA can be improved, the resolution reaction efficiency can be improved, and the preparation efficiency of the compound shown in the formula 2 by using the method can be further improved.
According to an embodiment of the present invention, in the step (1), the following steps are included: adding the compound 1 into an ethanol/water/acetic acid mixed solution, heating to 50-70 ℃, then keeping the temperature at 50-70 ℃, dropwise adding the mixed solution of L-DBTA and ethanol/water/acetic acid, stirring the obtained solution at 50-70 ℃ so as to carry out chiral resolution, then cooling to room temperature, collecting solids by centrifugation, and washing with ethanol. And stirring the filter cake in a mixed solvent of ethanol/water/acetic acid at 55 ℃ for 4 hours, cooling to room temperature, collecting the solid by centrifugation, washing with ethanol, and drying the filter cake in vacuum to obtain the compound shown in the formula 2, wherein the compound is a chiral compound. Therefore, the contact efficiency of the compound 1 and L-DBTA can be improved, the resolution reaction efficiency is improved, and the efficiency of preparing the compound shown in the formula 2 by using the method is further improved.
According to an embodiment of the invention, in the step (1), the molar ratio of the compound 1 to the L-DBTA is 1 (1.05-1.5), and preferably the molar ratio of the compound 1 to the L-DBTA is 1: 1.2. Thus, the efficiency of preparing the compound represented by formula 2 by the method can be further improved.
According to the embodiment of the invention, in the step (1), the compound 1 is contacted with L-DBTA at 50-70 ℃ and stirred for chiral resolution for 15-20 h. Therefore, the contact efficiency of the compound 1 and L-DBTA can be improved, the resolution reaction efficiency is improved, and the efficiency of preparing the compound shown in the formula 2 by using the method is further improved.
According to a specific embodiment of the present invention, in the step (1), the following steps are included: compound 1(30.0g, 0.1mol) was added to an ethanol/water/acetic acid mixture (600mL, formulation: obtained by mixing ethanol, water, acetic acid in a volume ratio of 7:3: 1), heated to 70 ℃, and then kept at 70 ℃ a mixture of L-DBTA (43.0g, 0.12mol) and ethanol/water/acetic acid (volume ratio of 7:3:1, 20mL) was added dropwise, the resulting solution was stirred at 70 ℃ for 16 hours, then cooled to room temperature, and the solid was collected by centrifugation and washed with ethanol (20 mL). After the filter cake was stirred in a mixed solvent of ethanol/water/acetic acid (7:3:1, 20mL) at 55 ℃ for 4 hours, it was cooled to room temperature, the solid was collected by centrifugation and washed with ethanol (20mL), and the filter cake was dried under vacuum to give the compound represented by formula 2.
According to an embodiment of the present invention, in the step (2), the contacting manner of the compound represented by formula 2, N-Diisopropylethylamine (DIPEA), and the compound represented by formula 3 is not particularly limited. Preferably, the solvent of the reaction is selected from THF. Therefore, the contact efficiency of the compound shown in the formula 2, DIPEA and the compound shown in the formula 3 can be improved, the reaction speed is increased, and the efficiency of preparing the compound shown in the formula 4 by using the method is further improved.
According to an embodiment of the present invention, in step (2), the packetThe method comprises the following steps: adding the compound 2, DIPEA and the compound 3 into THF at room temperature, and stirring at room temperature for 3.5-5 h. Reaction solution is concentrated to half volume and saturated NaHCO is added3Washing the solution, extracting with EA, drying, concentrating the organic phase, and purifying by column chromatography to obtain the compound shown in formula 4. Thus, the efficiency of preparing the compound represented by formula 4 using this method can be further improved.
According to an embodiment of the present invention, in the step (2), the molar ratio of the compound represented by the formula 2, DIPEA and the compound represented by the formula 3 is 1 (1.1-1.5) to (1.0-1.2), preferably the molar ratio of the compound represented by the formula 2, DIPEA and the compound represented by the formula 3 is 1: 1.2: 1. therefore, the utilization rate of the reactants is high, the waste of raw materials and reality is avoided, and the yield of the target compound is high.
According to an embodiment of the invention, in the step (2), the compound represented by the formula 2, DIPEA and the compound represented by the formula 3 are stirred at room temperature for 3.5-5 h.
According to an embodiment of the present invention, in the step (2), the column chromatography is eluted using a petroleum ether/ethyl acetate mixed solvent in a volume ratio of 10: 1. Thus, the efficiency of preparing the compound represented by formula 4 using this method can be further improved.
According to a specific embodiment of the present invention, in the step (2), the following steps are included: compound 2(20.0g, 30.3mmol), DIPEA (4.7g, 36.4mmol) and compound 3(7.1g, 30.3mmol) were added to THF (200mL) at room temperature and stirred at room temperature for 4 h. Reaction solution is concentrated to half volume and saturated NaHCO is added3The solution (50mL) is washed, extracted with EA (50mL), dried and concentrated in an organic phase, and purified by column chromatography (using a mixed solvent of petroleum ether and ethyl acetate in a volume ratio of 10: 1) to obtain the compound represented by formula 4.
According to an embodiment of the present invention, in step (3), the contacting manner of the compound represented by formula 4 with the base is not particularly limited. Therefore, the contact efficiency of the compound shown in the formula 4 and the alkali can be improved, the reaction speed is increased, and the efficiency of preparing the compound shown in the formula I by using the method is further improved.
According to an embodiment of the present invention, in the step (3), the following steps are included: to a mixture of dichloromethane and the aqueous base solution was added compound 4 portionwise at room temperature and stirred at room temperature for 2 h. After completion of the reaction, the organic layer was collected and the aqueous layer was extracted with dichloromethane, the organic layers were combined, dried and concentrated to give a brown solid. The collected solids were slurried with methyl tert-butyl ether. The solid was collected by centrifugation and washed with methyl tert-butyl ether and then dried under vacuum to give the compound of formula I. Therefore, the efficiency of preparing the compound shown in the formula I by using the method can be further improved.
According to an embodiment of the present invention, in step (3), the base is an organic base or an inorganic base, preferably the base is an inorganic base.
According to an embodiment of the present invention, in the step (3), the inorganic base is at least one selected from potassium hydroxide, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, cesium carbonate, potassium phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate, and preferably the inorganic base is selected from potassium hydroxide or sodium hydroxide.
According to a specific embodiment of the present invention, in the step (3), the following steps are included: to a mixture of dichloromethane (200mL) and 20% by mass aqueous KOH (40mL) was added compound 4(15.0g, 17.6mmol) portionwise at room temperature, and the mixture was stirred at room temperature for 2 h. After completion of the reaction, the organic layers were collected and the aqueous layer was extracted with dichloromethane (40mL), the organic layers were combined, dried and concentrated to give a brown solid. The collected solid was slurried with methyl tert-butyl ether (100 mL). The solid was collected by centrifugation and washed with methyl tert-butyl ether (50mL) and then dried in vacuo to give the compound of formula I in an amount of 8.3g, yield 94.6% and ee value 98.6%.
According to the examples of the present invention, the synthetic route of the compound avapritinib of formula I can be as follows:
compared with the prior art, the method for preparing avapritinib synthetically has at least the following beneficial effects: the method adopts the intermediate compound 1 which is easily obtained at present as a starting material, utilizes L-DBTA to carry out chemical resolution on the intermediate compound 1, then carries out halogenation reaction, and removes the L-DBTA to obtain the target compound molecule avapritinib. Compared with the existing synthetic route, the synthetic method has the advantages of multiple reaction steps and low yield, and chiral compounds are resolved by using a chiral column, so that the synthetic method greatly reduces the reaction steps, improves the total yield of the reaction, effectively reduces the cost of final products, and has good experimental operability.
Detailed Description
The following describes embodiments of the present invention in detail. The following examples are illustrative only and are not to be construed as limiting the invention. The examples, where specific techniques or conditions are not indicated, are to be construed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
EXAMPLE 1 Synthesis of Compound represented by formula 2
Compound 1(30.0g, 0.1mol) was added to an ethanol/water/acetic acid mixture (600mL, formulation: obtained by mixing ethanol, water, acetic acid in a volume ratio of 7:3: 1), heated to 70 ℃, and then kept at 70 ℃ a mixture of L-DBTA (43.0g, 0.12mol) and ethanol/water/acetic acid (volume ratio of 7:3:1, 20mL) was added dropwise, the resulting solution was stirred at 70 ℃ for 15 hours, then cooled to room temperature, and the solid was collected by centrifugation and washed with ethanol (20 mL). The filter cake was stirred in a mixed solvent of ethanol/water/acetic acid (7:3:1, 20mL) at 55 ℃ for 4 hours, then cooled to room temperature, the solid was collected by centrifugation and washed with ethanol (20mL), and the filter cake was vacuum-dried to give the compound represented by formula 2 in an amount of 27.4g with a yield of 41.5%.
Example 2 Synthesis of Compound represented by formula 2
Compound 1(30.0g, 0.1mol) was added to an ethanol/water/acetic acid mixture (600mL, preparation method: mixing ethanol, water, acetic acid in a volume ratio of 7:3: 1), heated to 50 deg.C, and then a mixture of L-DBTA (37.6g, 0.105mol) and ethanol/water/acetic acid (volume ratio of 7:3:1, 20mL) was added dropwise while maintaining at 50 deg.C, the resulting solution was stirred at 50 deg.C for 20 hours, then cooled to room temperature, the solid was collected by centrifugation and washed with ethanol (20 mL). The filter cake was stirred in a mixed solvent of ethanol/water/acetic acid (7:3:1, 20mL) at 55 ℃ for 4 hours, then cooled to room temperature, the solid was collected by centrifugation and washed with ethanol (20mL), and the filter cake was vacuum-dried to give the compound represented by formula 2 in an amount of 19.4g with a yield of 29.4%.
EXAMPLE 3 Synthesis of Compound represented by formula 2
Compound 1(30.0g, 0.1mol) was added to an ethanol/water/acetic acid mixture (600mL, formulation: obtained by mixing ethanol, water, acetic acid in a volume ratio of 7:3: 1), heated to 65 deg.C, and then kept at 65 deg.C, a mixture of L-DBTA (53.7g, 0.15mol) and ethanol/water/acetic acid (volume ratio of 7:3:1, 20mL) was added dropwise, the resulting solution was stirred at 65 deg.C for 18 hours, then cooled to room temperature, the solid was collected by centrifugation and washed with ethanol (20 mL). The filter cake was stirred in a mixed solvent of ethanol/water/acetic acid (7:3:1, 20mL) at 55 ℃ for 4 hours, then cooled to room temperature, the solid was collected by centrifugation and washed with ethanol (20mL), and the filter cake was vacuum-dried to give the compound represented by formula 2 in an amount of 24.9g with a yield of 37.7%.
Example 4 Synthesis of Compound represented by formula 4
Compound 2(20.0g, 30.3mmol), DIPEA (4.7g, 36.4mmol) and compound 3(7.1g, 30.3mmol) were added to THF (200mL) at room temperature and stirred at room temperature for 4 h. Reaction solution is concentrated to half volume and saturated NaHCO is added3The solution (50mL) was washed, extracted with EA (50mL), dried and the organic phase concentrated and purified by column chromatography (using a mixed solvent of petroleum ether and ethyl acetate in a volume ratio of 10: 1) to give the compound of formula 4 in an amount of 21.0g with a yield of 81.2%.
EXAMPLE 5 Synthesis of Compound represented by formula 4
Compound 2(20.0g, 30.3mmol), DIPEA (4.3g, 33.3mmol) and compound 3(7.8g, 33.3mmol) were added to THF (200mL) at room temperature and stirred at room temperature for 3.5 h. Reaction solution is concentrated to half volume and saturated NaHCO is added3Washing the solution (50mL), extracting with EA (50mL), drying, concentrating the organic phase, and purifying by column chromatography (using a mixed solvent of petroleum ether and ethyl acetate at a volume ratio of 10: 1) to obtain the compound of formula 4The compound showed, yield 19.2g, 74.3%.
EXAMPLE 6 Synthesis of Compound represented by formula 4
Compound 2(20.0g, 30.3mmol), DIPEA (5.9g, 45.45mmol) and compound 3(8.5g, 36.4mmol) were added to THF (200mL) at room temperature and stirred at room temperature for 5 h. Reaction solution is concentrated to half volume and saturated NaHCO is added3The solution (50mL) was washed, extracted with EA (50mL), dried and the organic phase concentrated and purified by column chromatography (using a mixed solvent of petroleum ether and ethyl acetate in a volume ratio of 10: 1) to give the compound of formula 4 in an amount of 19.9g and a yield of 77.0%.
Example 7 Synthesis of Avapritinib Compound of formula I
To a mixture of dichloromethane (200mL) and 20% by mass aqueous KOH (40mL) was added compound 4(15.0g, 17.6mmol) portionwise at room temperature, and the mixture was stirred at room temperature for 2 h. After completion of the reaction, the organic layers were collected and the aqueous layer was extracted with dichloromethane (40mL), the organic layers were combined, dried and concentrated to give a brown solid. The collected solid was slurried with methyl tert-butyl ether (100 mL). The solid was collected by centrifugation and washed with methyl tert-butyl ether (50mL) and then dried in vacuo to give the compound of formula I in an amount of 8.3g, yield 94.6% and ee value 98.6%.
LC-MS(APCI):m/z＝499.4(M+1)+。
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (13)
1. A method of synthesizing Avapritinib, comprising:
(1) contacting a compound represented by formula 1 with L-dibenzoyltartaric acid to obtain a compound represented by formula 2;
(2) contacting a compound represented by formula 2 with a compound represented by formula 3 to obtain a compound represented by formula 4;
(3) contacting a compound of formula 4 with a base to obtain a compound of formula I, Avapritinib,
in the step (1), the method comprises the following steps: adding the compound shown in the formula 1 into an ethanol/water/acetic acid mixed solution, heating to 50-70 ℃, then keeping the temperature at 50-70 ℃, dropwise adding the mixed solution of L-DBTA and ethanol/water/acetic acid, stirring the obtained solution at 50-70 ℃ so as to carry out chiral resolution, then cooling to room temperature, centrifugally collecting solids and washing with ethanol, stirring a filter cake in the mixed solvent of ethanol/water/acetic acid at 55 ℃ for 4 hours, cooling to room temperature, centrifugally collecting the solids, washing with ethanol, and vacuum-drying the filter cake to obtain the compound shown in the formula 2;
in the step (2), the method comprises the following steps: adding a compound shown as a formula 2, DIPEA and a compound shown as a formula 3 into THF at room temperature, stirring at room temperature for 3.5-5 h, concentrating a reaction solution to half volume, and adding saturated NaHCO3Washing the solution, extracting with EA, drying, concentrating the organic phase, and purifying by column chromatography to obtain the compound shown in formula 4.
2. The method according to claim 1, wherein in the step (1), the molar ratio of the compound represented by the formula 1 to L-DBTA is 1 (1.05-1.5).
3. The method according to claim 2, wherein in step (1), the molar ratio of the compound represented by formula 1 to L-DBTA is 1: 1.2.
4. The method according to claim 1, wherein in the step (1), the chiral resolution of the compound shown in the formula 1 is performed by contacting and stirring the compound with L-DBTA at 50-70 ℃ for 15-20 h.
5. The method according to claim 1, wherein in the step (2), the molar ratio of the compound represented by the formula 2 to the DIPEA to the compound represented by the formula 3 is 1 (1.1-1.5) to 1.0-1.2.
6. The method of claim 5, wherein in step (2), the compound of formula 2, DIPEA, and the compound of formula 3 are present in a molar ratio of 1: 1.2: 1.
7. the method as claimed in claim 1, wherein, in the step (2), the column chromatography is eluted with a mixed solvent of petroleum ether/ethyl acetate in a volume ratio of 10: 1.
8. The method of claim 1, wherein in step (3), the following steps are included: adding the compound shown in the formula 4 to a mixture of dichloromethane and the aqueous solution of the base in batches at room temperature, stirring at room temperature for 2h, collecting organic layers after the reaction is completed, extracting an aqueous layer by dichloromethane, combining the organic layers, drying and concentrating to obtain brown solid, slurrying the collected solid by methyl tert-butyl ether, collecting the solid by centrifugation, washing the solid by methyl tert-butyl ether, and then drying in vacuum to obtain the compound shown in the formula I.
9. The method according to claim 8, wherein in step (3), the base is an organic base or an inorganic base.
10. The method according to claim 9, wherein in step (3), the base is an inorganic base.
11. The method according to claim 10, wherein in step (3), the inorganic base is at least one selected from the group consisting of potassium hydroxide, sodium hydrogen carbonate, sodium carbonate, potassium hydrogen carbonate, potassium carbonate, cesium carbonate, potassium phosphate, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate.
12. The method according to claim 11, wherein in step (3), the inorganic base is selected from potassium hydroxide or sodium hydroxide.
13. The method according to claim 1, wherein in step (1), the following steps are included: adding 30.0g of the compound shown in the formula 1 into 600mL of ethanol/water/acetic acid mixed solution, heating to 70 ℃, then maintaining the temperature at 70 ℃, dropwise adding 43.0g L-DBTA and 20mL of ethanol/water/acetic acid mixed solution, stirring the obtained solution at 70 ℃ for 16 hours, then cooling to room temperature, collecting solid through centrifugation and washing with 20mL of ethanol, stirring filter cake in 20mL of ethanol/water/acetic acid mixed solvent at 55 ℃ for 4 hours, cooling to room temperature, collecting solid through centrifugation and washing with 20mL of ethanol, and drying the filter cake in vacuum to obtain the compound shown in the formula 2; wherein the volume ratio of ethanol, water and acetic acid in the ethanol/water/acetic acid mixed solution is 7:3: 1;
the step (2) comprises the following steps: 20.0g of the compound represented by the formula 2, 4.7g of DIPEA, and 7.1g of the compound represented by the formula 3 were added to 200mL of THF at room temperature, and the mixture was stirred at room temperature for 4 hours, and 50mL of saturated NaHCO was added to the reaction mixture in a half volume of the reaction solution concentrated3Washing the solution, extracting with 50mL of EA, drying, concentrating an organic phase, and purifying by column chromatography to obtain a compound shown in a formula 4;
in the step (3), the method comprises the following steps: after the reaction was completed, the organic layer was collected and the aqueous layer was extracted with 40mL of dichloromethane, the organic layers were combined, dried and concentrated to give a brown solid, the collected solid was slurried with 100mL of methyl t-butyl ether, the solid was collected by centrifugation and washed with 50mL of methyl t-butyl ether, and then dried under vacuum to give the compound of formula I in an amount of 8.3g, a yield of 94.6%, and an ee value of 98.6%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911359971.4A CN110938077B (en) | 2019-12-25 | 2019-12-25 | Method for synthesizing Avapritinib |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911359971.4A CN110938077B (en) | 2019-12-25 | 2019-12-25 | Method for synthesizing Avapritinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110938077A CN110938077A (en) | 2020-03-31 |
| CN110938077B true CN110938077B (en) | 2021-04-27 |
Family
ID=69912196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911359971.4A Active CN110938077B (en) | 2019-12-25 | 2019-12-25 | Method for synthesizing Avapritinib |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110938077B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3057969T3 (en) | 2013-10-17 | 2018-09-24 | Blueprint Medicines Corp | COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT |
| MX2021012469A (en) | 2019-04-12 | 2022-01-18 | Blueprint Medicines Corp | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases. |
| CN111454217A (en) * | 2020-05-20 | 2020-07-28 | 苏州明锐医药科技有限公司 | Preparation method of apltinib intermediate |
| CN111471020B (en) * | 2020-05-20 | 2022-03-08 | 苏州立新制药有限公司 | Preparation method of apltinib intermediate |
| HU231413B1 (en) * | 2021-02-26 | 2023-08-28 | Egis Gyógyszergyár Zrt. | Process for the preparation of avapritinib and intermediates for the process |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103880823B (en) * | 2012-12-21 | 2017-12-05 | 广东东阳光药业有限公司 | Application as the spiro-compound of hepatitis c inhibitor and its in medicine |
| DK3057969T3 (en) * | 2013-10-17 | 2018-09-24 | Blueprint Medicines Corp | COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT |
| PT3355890T (en) * | 2015-10-01 | 2022-01-19 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| KR20230162137A (en) * | 2016-08-16 | 2023-11-28 | 베이진 스위찰랜드 게엠베하 | (S)-7-(1-Acryloylpiperidin-4-yl)-2-(4-Phenoxyphenyl)-4,5,6,7-tetra-Hydrazolo[1,5-a]Pyrimidine-3-Carboxamide, Preparation, and Uses Thereof |
| US11459334B2 (en) * | 2018-04-16 | 2022-10-04 | Shenzhen Targetrx, Inc. | Substituted pyrrolo[2,1-f][1,2,4]triazines as KIT and/or PDGFR-α inhibitors |
-
2019
- 2019-12-25 CN CN201911359971.4A patent/CN110938077B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110938077A (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110938077B (en) | Method for synthesizing Avapritinib | |
| Evano et al. | Metal-mediated C–O bond forming reactions in natural product synthesis | |
| CN110950872A (en) | Method for preparing targeted anticancer drug avapritinib | |
| CN106928236B (en) | A kind of synthesis technology of Rui Boxini | |
| JP7292501B2 (en) | Crystal forms of CD73 inhibitors | |
| CN111138443B (en) | Preparation method for total synthesis of 4' -demethylepipodophyllotoxin | |
| CN108947949B (en) | Anxiolytic deuterated compounds and medical application thereof | |
| CN107118215B (en) | A kind of preparation method for treating breast cancer medicines Rui Boxini intermediate | |
| CN102146107A (en) | Synthesis and anti-tumor activity of (S)-2-hydroxyalkyl-1,4-dihydroxyl-9-10-anthraquinone and glycosyl conjugates | |
| CN110655506B (en) | Preparation method of tegafur | |
| CN112341377A (en) | Heterocyclic compound and application thereof | |
| CN108218798B (en) | Preparation method of Apabetalone | |
| CN104592254B (en) | The synthetic method of everolimus | |
| JP2019131483A (en) | Method for producing evodiamine | |
| CN111116477B (en) | Synthesis process of doramelamine | |
| CN110655507B (en) | Preparation method of anti-tumor medicine tegafur | |
| CN106977543A (en) | The preparation technology of improved Suo Feibuwei intermediates | |
| CN107739328B (en) | Preparation method of key intermediate 1 for synthesizing barretinib | |
| CN111533733A (en) | Preparation method of novel nifuratel series derivatives | |
| CN113573777A (en) | Prophylactic or therapeutic agent for cancer | |
| CN114262327B (en) | Preparation process of HER2 small-molecule inhibitor picatinib | |
| CN111662233B (en) | Method for synthesizing 4-chloro-1H-imidazole-2-carboxylic acid ethyl ester by one-step method | |
| CN110845406B (en) | Preparation method of quinoline compound | |
| CN110615751A (en) | Preparation method of 2-oxo-thiopropionamide | |
| CN111499570B (en) | Synthesis method of AV-45 intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |